Clinical Trial Update: Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating switching HIV-1 patients from ritonavir-boosted protease inhibitor regimens with two NRTIs to a fixed-dose tablet of emtricitabine/ri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• emtricitabine, rilpivirine, tenofovir disoproxil fumarate (emtricitabine; rilpivirine; tenofovir disoproxil fumarate)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2013-04-19